Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....
Streetwise Reports | October 4, 2019 |

Top Pick Status Given to Small-Cap with Pain Drug Candidate

The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. In a July 10 research note, analyst Douglas Loe reported that Echelon Wealth Partners bestowed Top Pick status on Antibe Therapeutics Inc. (ATE:TSX.V...
Streetwise Reports | July 19, 2019 |

Buzz on the Bullboards: Stocks making headlines

It can be hard to know when to make a move when every day looks crazier than the last. Traders don’t not know what to expect coming in tomorrow’s news cycle … but you can bet the markets are going to be volatile day-to-day. This has bee...
Jonathon Brown | October 12, 2023 |

Will Fed’s New Balance Sheet Policy be a Reason to Buy Gold?

As always, most analysts focus not on what they really should. After March FOMC meeting, everyone was talking about the more dovish dot-plot . But the Fed also announced that it will end the unwinding of its balance sheet in September. As these changes are revolutionary...
Arkadiusz Sieron | April 29, 2019 |

The May FOMC Meeting Is Over. They Say Every Cloud Has a Silver Lining...

The May FOMC statement didn’t bring much of a surprise. Fed Chair Powell remained upbeat in his assessment of the U.S. economy while dismissing low inflation as transitory. Gold has initially jumped, only to keep declining later. What has actually happened yest...
Arkadiusz Sieron | May 3, 2019 |

Buzz on the Bullboards: ‘Tis the Season for a Rebound?

Once the American Thanksgiving passes, the mood in North American markets seems to shift dramatically as investors contend with holidays, gifts, and vacations on one hand, with the end of their fiscal years on the other. Companies also look to end the calendar year on...
Stockhouse Editorial | December 1, 2021 |

Buzz on the Bullboards: Top Names in Mining, Cannabis, & Industrial Stocks

Having received UL 2723 ECOLOGO Certification for Mineral Exploration Companies last week, Critical Elements Lithium Corporation ( TSX-V: CRE , Forum ) announced this week that it had retained the services of Metso Outotec and WSP in Canada (WSP) to prepare a Pha...
Stockhouse Editorial | June 10, 2021 |

Standard Lithium in Final Stages of De-risking New Recovery Method; ...

Standard Lithium in Final Stages of De-risking New Recovery Method; Giant JV Partner Lanxess Will Fully Fund Capex When Successful The Critical Investor delves into this lithium firm's recovery method for its Arkansas project and why it may succeed when other companie...
Streetwise Reports | September 26, 2019 |

Unique Value-Added Antiviral Vaccine Technology Platform

(Click to play video.) Founded in 2018 to improve on protein haptenization and leverage previous vaccine development in the field, Vancouver, BC-based BioVaxys Technology Corp . ( CSE.BIOV , OTCQB: BVAX , Forum ) is a clinical stage biotechnology company that...
Dave Jackson | September 14, 2021 |